1. A real‐world comparison of docetaxel versus abiraterone acetate for metastatic hormone‐sensitive prostate cancer
- Author
-
Igor Tsaur, Isabel Heidegger, Jasmin Bektic, Mona Kafka, Roderick C. N. van denBergh, Jarmo C. B. Hunting, Anita Thomas, Maximilian P. Brandt, Thomas Höfner, Eliott Debedde, Constance Thibault, Paola Ermacora, Fabio Zattoni, Silvia Foti, Alexander Kretschmer, Guillaume Ploussard, Severin Rodler, Gunhild vonAmsberg, Derya Tilki, Christian Surcel, Barak Rosenzweig, Moran Gadot, Giorgio Gandaglia, Robert Dotzauer, and EAU‐YAU Prostate Cancer Working Party
- Subjects
chemotherapy ,hormonal therapy ,hormone‐sensitive ,metastasis ,prostate cancer ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background Docetaxel (D) or secondary hormonal therapy (SHT) each combined with androgen deprivation therapy (ADT) represent possible treatment options in males with metastasized hormone‐sensitive prostate cancer (mHSPC). Real‐world data comparing different protocols are lacking yet. Thus, our objective was to compare the efficacy and safety of abiraterone acetate (AA)+ADT versus D+ADT in mHSPC. Methods In a retrospective multicenter analysis including males with mHSPC treated with either of the aforementioned protocols, overall survival (OS), progression‐free survival 1 (PFS1), and progression‐free survival 2 (PFS2) were assessed for both cohorts. Median time to event was tested by Kaplan–Meier method and log‐rank test. The Cox‐proportional hazards model was used for univariate and multivariate regression analyses. Results Overall, 196 patients were included. The AA+ADT cohort had a longer PFS1 in the log‐rank testing (23 vs. 13 mos., p
- Published
- 2021
- Full Text
- View/download PDF